Matthew J. Matasar, MD

Articles

Role of Testing in Treatment Decisions - ClonoSeq, PhaseSeq, MRD+Disease

January 20th 2025

A concise discussion of second-line treatment strategies for DLBCL, highlighting preferred regimens for transplant-eligible and ineligible patients, as well as treatment approaches based on the timing of relapse.

Future Considerations for Front-line Treatment of DLBCL

January 20th 2025

An overview of key studies and updates from ASH 2024 offering new insights into subsequent treatment strategies and safety management in the first-line setting for DLBCL.

The Evolving First-line Treatment Approach for DLBCL

January 15th 2025

An exploration of how first-line treatment practices for DLBCL have evolved with new options, emphasizing the role of relapsed/refractory disease risk in guiding treatment selection.

Insights from POLARIX: How do Novel Perspectives Influence Treatment Outcomes in DLBCL?

January 15th 2025

An expert discussion on evolving first-line treatment strategies for newly diagnosed diffuse large B-cell lymphoma (DLBCL), incorporating insights from the 2024 NCCN guidelines, unmet needs in 1L therapies, and the impact of POLARIX trial updates on the use of Pola+R-CHP in clinical practice.

Emerging Updates in Front-line Treatment Approach of DLBCL

January 3rd 2025

Matthew Matasar, MD and Nilajan Ghosh, MD, PhD, discuss first-line treatment strategies for DLBCL, including factors influencing treatment selection, unmet needs in first-line treatment options, the impact of the 2024 NCCN guideline updates, and practical guidance for community practitioners following insights from the POLARIX trial.

Dr Matasar on the Use of Odronextamab Monotherapy in R/R DLBCL Following CAR T-Cell Therapy

December 10th 2024

Matthew Matasar, MD, discusses treatment with odronextamab monotherapy in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.

Dr Matasar on the Design of the OLYMPIA-3 Trial in DLBCL

June 13th 2024

Matthew Matasar, MD, discusses the design of the phase 3 OLYMPIA-3 trial of odronextamab plus CHOP in treatment-naive intermediate- or high-risk DLBCL.

BTK Degraders and Other Targets in Mantle Cell Lymphoma

February 28th 2023

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

The Role of Bispecific Antibodies in Mantle Cell Lymphoma

February 21st 2023

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

Treating Patients With MCL Who Progress on BTK Inhibitors

February 21st 2023

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

CAR T-Cell Therapy in Patients With MCL: Clinical Trial and Real-World Data

February 14th 2023

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

Patient Profile 2: A 60-Year-Old Man With Mantle Cell Lymphoma

February 14th 2023

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

Approaches to Treating Patients With High-Risk Mantle Cell Lymphoma

February 7th 2023

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

Selecting the Appropriate BTKi in MCL and Potential Role of Pirtobrutinib

February 7th 2023

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

BTK Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

January 31st 2023

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

SHINE Study: Ibrutinib Plus Bendamustine and Rituximab in Elderly Patients With MCL

January 31st 2023

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

Is There a Role for Response-Adapted Treatment in Mantle Cell Lymphoma?

January 24th 2023

Matthew J. Matasar, MD, discusses the prospect of using minimal residual disease to guide treatment decisions in mantle cell lymphoma.

TRIANGLE Study: Ibrutinib vs Stem Cell Transplant in Younger Patients With MCL

January 24th 2023

Boyu Hu, MD, and Bijal D. Shah, MD, provide their thoughts on the TRIANGLE study looking at ibrutinib versus stem cell transplant in MCL.

Patient Profile 1: A 74-Year-Old Man Diagnosed With Mantle Cell Lymphoma

January 17th 2023

A patient profile of a 74-year-old man diagnosed with mantle cell lymphoma who receives treatment with a non-covalent BTK inhibitor is presented by Alexey V. Danilov, MD, PhD.

Overview of Mantle Cell Lymphoma and First-Line Treatment Options

January 17th 2023

Alexey V. Danilov, MD, PhD, provides an overview of the pathophysiology, symptoms, and subtypes of mantle cell lymphoma.